Osmotica up after brokerage starts coverage with 'buy'

RVL Pharmaceuticals

23/12/2021 18:54

** Biopharmaceutical firm's shares  OSMT.O  up 5.6% at $1.12
- set for its best day in over two weeks
    ** Brokerage Wainwright initiates coverage with "buy"
rating, sets PT of $5
    ** Market has overlooked droopy eyelid treatment Upneeq's
potential, given OSMT's past focus on complex generics, which
the company exited earlier this year to concentrate on Upneeq -
Wainwright
    ** Upneeq has gained increasing attention in the aesthetics
space, Wainwright says, adding that it sees total peak sales of
nearly $700 mln in 2035, predominantly in aesthetics
    ** Up to last close, stock had fallen ~74% YTD

 (Reporting by Akash Sriram in Bengaluru)
 ((Akash.Sriram@thomsonreuters.com;))